CT1812
CT1812 is an oral medication being developed by Cognition Therapeutics, now in clinical testing, to possibly treat mild-to-moderate Alzheimer’s disease by preventing the build up of beta-amyloid in the brain.| Alzheimer's News Today
CT1812 is an oral medication being developed by Cognition Therapeutics, now in clinical testing, to possibly treat mild-to-moderate Alzheimer’s disease by preventing the build up of beta-amyloid in the brain.| Alzheimer's News Today
Marisa Wexler is a senior science writer for Alzheimer's News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Learn more about the symptoms of Alzheimer’s disease, the most common form of dementia, and its several stages. Alzheimer's symptoms may be different for each patient.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today
